雄激素和雌激素受体在肺腺癌和肺鳞癌中的表达  

Expressions of androgen and estrogen receptors in lung adenocarcinoma and squamous cell carcinoma

作　　者：刘先本[1] 王淑玲[2] 闫明[1] 陈小兵[3] 张瑞祥[1] 李印[1] 

机构地区：[1]河南省肿瘤医院胸外科,郑州450008 [2]郑州大学基础医学院 [3]河南省肿瘤医院肿瘤内科,郑州450008

出　　处：《江苏医药》2010年第9期1000-1002,F0003,共4页Jiangsu Medical Journal

基　　金：河南省科技攻关基金项目(082102310116)

摘　　要：目的探讨雄激素受体和雌激素受体在肺腺癌、鳞癌中的表达及其与预后的关系。方法应用免疫组化SP法检测54例肺腺癌和78例鳞癌组织标本中雄激素受体(AR)和雌激素受体(ER)的表达,并分析其与临床特性及生存率的关系。结果 AR和ER总阳性率分别为21.2%(28/132)和18.2%(24/132)。非小细胞肺癌(NSCLC)组织中AR的阳性表达与TNM分期及N分期(淋巴结转移情况)相关。AR表达阳性组3年生存率显著低于阴性组(21.4%vs.45.2%)(P<0.05);ER表达阳性组3年生存率低于阴性组(29.2%vs.42.6%)(P>0.05)。结论 AR的阳性表达与NSCLC淋巴结转移和肿瘤进展可能相关,并且预后较差。Objective To investigate the expressions of androgen receptor（AR） and estrogen receptor（ER） in non-small cell lung carcinoma（NSCLC）.Methods Expressions of AR and ER were examined using immunohistochemical method in adenocarcinoma（54 cases） and squamous carcinoma（78 cases）.Results The total positive expression rates were 21.2%（28/132） for AR and 18.2%（24/132） for ER.The positive rate of AR was significantly correlated with TNM stages and lymph node metastasis（P0.05）.The three-year survival rate was significantly lower in AR-positive group than that in AR-negative group（21.4% vs.45.2%）（P0.05）.The three-year survival rate was lower in ER-positive than that in ER-negative（29.2% vs.42.6%）（P0.05）.Conclusion The positive expression of AR may play a role in the progression and lymph node metastasis of NSCLC and predict a poor prognosis.

关 键 词：非小细胞肺癌 雄激素受体 雌激素受体 

分 类 号：R734[医药卫生—肿瘤]